Sahm Adrangi Issues Report on Pharma Company

Business, Business Leader, CEO, Financial, Financial Advice, Investment Advice, Investor

When you are looking to invest your personal capital, doing the right level of financial diligence is very important. While most people focus on reading reports about companies that discuss their future growth potential, other people and up researching companies that have potential for big losses.

When looking for opportunities that could result in a company losing stock value, you could end up making a lot of money through short selling and buying put options. One individual that continues to provide insight into companies that may have overvalued stocks is Sahm Adrangi, who is the principal of Kerrisdale Capital.

Over the past few years, Sahm Adrangi has issued a number of very insightful reports that discussed the financial condition of many different companies. While many of his views end up being disputed, he is often proven correct in his assessment. Over the past few weeks, Sahm Adrangi issued a report on the prospects of Proteostasis Therapeutics.

Overall, Sahm Adrangi gave a number of good reasons why he thinks the company will not continue to see a high stock price. Overall, the future prognosis of Proteostasis Therapeutics will hinge on the company’s ability to bring a new drug they are working on to the next stage of a clinical trial. The Proteostasis Therapeutics company was recently able to bring a drug used to treat cystic fibrosis through Stage 2 testing with the FDA. While this is a major accomplishment, there is still a lot more work that needs to be done in order for them to be able to bring it to market. While Proteostasis Therapeutics has seen a big increase in value due to the Stage 2 test, the company could suffer if it is not successful in bringing it through Stage 3.

According to Adrangi, there is plenty of reason to doubt that Proteostasis Therapeutics will be able to bring their next drug through the next stage of clinical trials. He also believes that the company has tried to stay compliant by producing interim reports, but he believes that a lot of the information provided has been swept under the rug.

http://www.businessinsider.com/meet-hedge-funder-sahm-adrangi-2013-10

Paul Mampilly Offers Stock Investment Advice for the Average Investor

Businessman, Investor

Paul Mampilly is a man with his finger on the pulse. He is a successful American investor, hedge fund manager, and a winner of the Templeton Foundation Investment award. His latest pitch is for a mid-western company that he feels is on the most important medical breakthrough the world has ever known. The breakthrough may be such that diseases, once thought to be death sentences, will become a past memory.

The breakthrough is the work of a $1.5 billion-dollar company that is pioneering the field of precision medicine. Every person’s DNA provides a blueprint. The company’s medicine will offer a solution to fight disease based on a person’s genetic makeup. It will be like fitting a person with a tailor-made suit. The medications will also help prevent a disease from happening in the first place. In effect, this means that diseases like diabetes, Parkinson’s, or even heart disease, can be eliminated simply by adjusting for the individual’s DNA patterns.

This would indeed be an amazing medical breakthrough. Paul Mampilly is currently the Senior Editor of several publications at Banyan Hill Publishing. His newsletter, Profits Unlimited, offers information and analysis of stocks that he targets for higher gains. Paul Mampilly received his MBA in 1996 from Fordham University. Mampilly eventually grew tired of the Wall Street pace and earning money for the nation’s top 1%. He decided to shift his focus to helping average individuals to earn income on their own investments.

Mampilly has more than 40,000 subscribers who take his monthly investment advice quite seriously. Many of his successful followers have earned money without having to invest in risky options or bets. That eases the strain for a lot of junior or novice investors who look to make a profit in the stock market.

Paul Mampilly comes from a humble background, and he grew up poor. He understands what it is like to live on both sides of the fence. As a result, he has a soft spot for anyone looking to move up in the world. He is a talented and bright individual who will likely continue to offer investment advice for the average person looking to break into the market.

Learn More: www.youtube.com/watch?v=rEOrH47cGNw

Ted Bauman Is Taking Banyan Hill Publishing To The Next Level

Entrepreneur, Investor

Investing is one of the most important and basic things just about anybody does in order to protect their future. If you want to do everything you can to make sure your future is taken care of, you’re going to have to find a way to prepare. Ted Bauman understands this better than anybody else and he does just about everything he can to give his readers what they need to be ready for the future. Most people who read what he publishes are able to take their investments to the next level. Now, he wants to take things to the next level.

Banyan Hill Publishing provides a number of books that discuss how to invest in the future and the methods necessary to get ahead in today’s market. These methods appear to be incredibly effective for the vast majority of people and he has even managed to reach audiences that normally wouldn’t consider investment opportunities on seekingalpha.com. Besides investment in general, he’s managed to make himself a guru for those interested in very specific areas of the financial world. For those more esoteric problems, Bauman’s literature gives solutions appropriate for just about any situation that might come up.

Read more on stocktwits.com

One of the more important areas of discussion for Bauman is asset protection. He has made it his goal to ensure that people are able to prevent market crashes and other issues from affecting their ability to live the lifestyle they want. Beyond investment itself people need to be able to take care of what they already have. Ted Bauman’s advice has helped countless people prepare for their future and it continues to give many others what they need to expand and provide their assets with the ability to expand. Things are looking better for Ted Bauman and Banyan Hill Publishing, but things can be brighter.

According to banyanhill.com Ted Bauman has made Banyan Hill Publishing one of the most beloved financial literature companies out there. He has made it clear that he wants to give people a leg up in the investment world and so far that appears to be happening. The world of investment is a scary one no matter how experienced you are. Countless investors have lost everything and had their dreams crushed. If Banyan Hill Publishing can eliminate even a small percentage of that, they have the potential to create something much greater. Each newly published book brings Bauman’s dream that much closer.

Find more about Ted Bauman: https://www.bloomberg.com/research/stocks/private/person.asp?personId=264684898&privcapId=109183793&previousCapId=109183793&previousTitle=The%20Sovereign%20Society

James Dondero; Co-founder of Highland Capital Management

Investor

James David Dondero is a well-renowned business person. He is well known for being the co-founder of the Highland Capital Management. The Capital Management organization was formed in 1993. The group is mainly focused on public equity, structured investments, distressed investment funds and fixed income. The company portfolio is estimated to be worth about $2.44 billion, based on the recent findings from the SEC filings.

According to the recent SEC filings, Highland Capital Management stepped up their game in the New York Stock Exchange (Nexpoint Credit Strategies Fund). The organization has now accumulated a total of 793,036 shares, of which 5percent comprises of the outstanding Common Stock. On the other hand, the co-founder James Dondero is among the major shareholders of the Nexpoint Credit Strategies. James Dondero owns a sum that amounts to 3.01 million shares, of which regarding percentage, the amount totals to 18.8 percent of the company’s total worth.

During the end of the third quarter of the year, Highlands was able to purchase 20,286 new shares in Nexpoint. The total amount of new shares purchased amounted to a lump sum of $11.68 million. As a result, Highland capital management is the largest shareholder in Nexpoint. As for Nexpoint Credit Strategies Fund, the management task is well catered for by the Nexpoint Advisors.

Nexpoint Credit Strategies Fund is a very suitable example of a closed-end fund. The fund was sub-divided into two individual companies. The two different trade businesses that emerged were Nexpoint Residential Trust Incorporation and Nexpoint Credit Strategies Fund. The fund is mainly aimed at seeking capital and income appreciation. So as to achieve their goal, they invest equity as well as below investment grade debts. The portfolio of Nexpoint Credit’s is quite remarkable. The company is gauged to be worth around $600 million. Also, the company’s net assets are calculated to be worth approximately $382 million.

In comparison with other close-end funds, the Nexpoint Credit is entirely different. The difference occurs due to the attempts of trying to exceed the resurrection of the HFR Global Hedge Fund Indexes as well as CS Hedge Fund. Over the years, the fund has accumulated various holdings. Most of the holdings are under James Dondero’s name or Highland Capital.

Though the fund had experienced a slight downfall, it is now backing on track. The fund is up and running very well. In fact, Nexpoint had decided to offer a $2.4 per share regarding dividends on a monthly basis. The Dividends are only applicable to the shareholders.